This site is intended for U.S. healthcare professionals.
Menu
Close
Menu
Close
Pivotal Trial Results
Post-Hoc Analysis Results
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Example of description text sitting alongside header
Example of description text sitting alongside header
Example of description text sitting alongside header
IGA 0/1: Adults
IGA 0/1: Pediatrics
EASl-90: Adults
JADE COMPARE evaluated efficacy and safety endpoints up to 16 weeks in a randomized, double-blind, double-dummy, placebo-controlled, parallel-group clinical trial in which 837 patients aged 18 years and older with moderate-to-severe AD received CIBINQO 100 mg, CIBINQO 200 mg, dupilumab 300 mg, or placebo, with background TCS in all arms. Dupilumab was an active control except for the one head-to-head endpoint of PP-NRS4 at week 2. Patients had a history of inadequate response to topical therapies or required systemic therapy.1-3
See full study design >
RECOMMENDED DOSE: CIBINQO 100 mg
If response to 100 mg is inadequate, consider increasing to 200 mg. Discontinue if inadequate response is seen after dose increase.
Photos show specific areas of the skin of clinical trial patients diagnosed with moderate-to-severe AD. These may not reflect the full extent or appearance of AD elsewhere on their skin. See clinical trial results throughout. Individual results may vary.
Baseline
Week 2
Week 12
7-day run-in of nonmedicated emollients was required.
DOSE: 200 mg + TCS
AGE: 21
SEX: Male
TRIAL: COMPARE
IGA AT BASELINE: 4 (Severe)
7-day run-in of nonmedicated emollients was required.
DOSE: 200 mg + TCS
AGE: 21
SEX: Male
TRIAL: COMPARE
7-day run-in of nonmedicated emollients was required.
DOSE: 200 mg + TCS
AGE: 21
SEX: Male
TRIAL: COMPARE
IGA AT BASELINE: 4 (Severe)
IGA AT WEEK 12: 0 (Clear)
200 mg is not an approved starting dose. Please see dosing information here.
Reference text - Paragraph text - Lorem ipsum dolor sit amet, consectetur adipiscing elit. Fusce bibendum felis id turpis interim eleifend. Ut egestas eleifend nunc sed mollis.
Face
Example
Baseline
Week 2
Week 12
200 mg is not an approved starting dose. Please see dosing information here.
JADE TEEN evaluated efficacy and safety endpoints up to 12 weeks in a phase 3, randomized, double-blind, placebo-controlled clinical trial in which 284 pediatric patients aged 12 to <18 years with a body weight of ≥25 kg and moderate-to-severe AD received CIBINQO 100 mg, CIBINQO 200 mg, or placebo with background TCS in all arms.1,2
See full study design >
RECOMMENDED DOSE: CIBINQO 100 mg
If response to 100 mg is inadequate, consider increasing to 200 mg. Discontinue if inadequate response is seen after dose increase.
JADE COMPARE evaluated efficacy and safety endpoints up to 16 weeks in a randomized, double-blind, double-dummy, placebo-controlled, parallel-group clinical trial in which 837 patients aged 18 years and older with moderate-to-severe AD received CIBINQO 100 mg, CIBINQO 200 mg, dupilumab 300 mg, or placebo, with background TCS in all arms. Dupilumab was an active control except for the one head-to-head endpoint of PP-NRS4 at week 2. Patients had a history of inadequate response to topical therapies or required systemic therapy.1-3
See full study design >
RECOMMENDED DOSE: CIBINQO 100 mg
If response to 100 mg is inadequate, consider increasing to 200 mg. Discontinue if inadequate response is seen after dose increase.
Resources such as the discussion guide and patient brochure can help
A product representative is available to help you learn more about CIBINQO
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2024 Pfizer Inc. All rights reserved.